Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09‐related pneumonia: an individual participant data meta‐analysis

The impact of neuraminidase inhibitors (NAIs) on influenza‐related pneumonia (IRP) is not established. Our objective was to investigate the association between NAI treatment and IRP incidence and outcomes in patients hospitalised with A(H1N1)pdm09 virus infection.

• Publication year

  2015

• Venue

  Influenza and Other Respiratory Viruses

• Publication date

  2015-11-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/irv.12363PMID 26602067PMCID 4814862
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09‐related pneumonia: an individual participant data meta‐analysis

  2015cited by this paper
• Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials.

  2015cited by this paper
• Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children

  2014cited by this paper
• Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.

  2014cited by this paper
• Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.

  2014cited by this paper
• Antivirals for Treatment of Influenza

  2012cited by this paper
• Impact of Neuraminidase Inhibitor Treatment on Outcomes of Public Health Importance During the 2009–2010 Influenza A(H1N1) Pandemic: A Systematic Review and Meta-Analysis in Hospitalized Patients

  2012cited by this paper
• Antivirals for Treatment of Influenza: A Systematic Review and Meta-Analysis of Observational Studies

  2012cited by this paper
• Risk factors for mechanical ventilation in U.S. children hospitalized with seasonal influenza and 2009 pandemic influenza A*

  2012cited by this paper
• Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09.

  2012cited by this paper
• Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.

  2012cited by this paper
• Complications and outcomes of pandemic 2009 Influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza?

  2011cited by this paper
• Clinical and laboratory features distinguishing pandemic H1N1 influenza-related pneumonia from interpandemic community-acquired pneumonia in adults

  2011cited by this paper
• Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study.

  2011cited by this paper
• Reducing Occurrence and Severity of Pneumonia Due to Pandemic H1N1 2009 by Early Oseltamivir Administration: A Retrospective Study in Mexico

  2011cited by this paper
• Pneumonia Complicating Pandemic (H1N1) 2009: Risk Factors, Clinical Features, and Outcomes

  2011cited by this paper
• Risk factors of A/H1N1 etiology in pneumonia and its impact on mortality.

  2011cited by this paper
• Characteristics of pregnant Japanese women who required hospitalization for treatment of pandemic (H1N1) 2009--low mortality rate may be due to early antiviral use.

  2011cited by this paper
• Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry.

  2010cited by this paper
• United Kingdom first wave ( May outcome with pandemic A / H 1 N 1 influenza : Risk factors for hospitalisation and poor

  2010cited by this paper
• Outcomes of adults hospitalised with severe influenza

  2010cited by this paper
• Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California.

  2009cited by this paper
• Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico.

  2009cited by this paper
• Viral Loads and Duration of Viral Shedding in Adult Patients Hospitalized with Influenza

  2009cited by this paper
• Antiviral treatment for patients hospitalized with severe influenza infection may affect clinical outcomes.

  2008cited by this paper
• Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada.

  2007cited by this paper
• Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

  2003cited by this paper
• Imaging of pneumonia: trends and algorithms.

  2001cited by this paper
• Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity.

  1997cited by this paper
• Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid.

  1974cited by this paper

• Comparison Between Clinical Outcomes in Influenza A and B Infections: A Multicenter Retrospective Cohort Study

  2025cites this paper
• Antiviral Bioactive Compounds: Their Activities and Underlying Mechanisms Against Human Viral Infections.

  2025cites this paper
• Use of Influenza Antivirals in Pandemic Response.

  2025cites this paper
• Risk Factors for Severe Influenza in Children

  2025cites this paper
• Benefit of early oseltamivir therapy for adults hospitalized with influenza A: an observational study.

  2024cites this paper
• The efficacy of azithromycin in the treatment of influenza A infection: A systematic review

  2024cites this paper
• Timing of influenza antiviral therapy and risk of death in adults hospitalized with influenza-associated pneumonia, FluSurv-NET, 2012-2019.

  2024cites this paper
• Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials

  2024cites this paper
• Polydopamine-based nanomedicines for efficient antiviral and secondary injury protection therapy

  2023cites this paper
• Influenza presentations and use of neuraminidase inhibitors by Australian general practice registrars: a cross-sectional analysis from the ReCEnT study

  2023cites this paper
• Evaluating confounding control in estimations of influenza antiviral effectiveness in electronic health plan data.

  2022cites this paper
• Updates in the management of respiratory virus infections in ICU patients: revisiting the non-SARS-CoV-2 pathogens

  2022cites this paper
• Wearable Sensor-Based Detection of Influenza in Presymptomatic and Asymptomatic Individuals

  2022cites this paper
• Virologische Erkrankungen auf der Intensivstation

  2021influential citation
• Flu-IV score: a predictive tool for assessing the risk of invasive mechanical ventilation in patients with influenza-related pneumonia

  2021cites this paper
• Clinical study of invasive pulmonary aspergillosis following influenza A H1N1

  2021cites this paper
• Comparison of Hospitalization and Death Frequencies in Influenza Outpatients Treated with Baloxavir marboxil or Neuraminidase Inhibitors： an Observational Database Study

  2021cites this paper
• The severity and risk factors for mortality in immunocompromised adult patients hospitalized with influenza-related pneumonia

  2021cites this paper
• Complications of Cardiovascular Events in Patients Hospitalized with Influenza-Related Pneumonia

  2021cites this paper
• Antiviral use is associated with a decrease in the rate of influenza-related complications, health care resource utilization, and costs

  2021cites this paper
• Rationale for azithromycin in COVID-19: an overview of existing evidence

  2021cites this paper
• Concentrated Secretome of Adipose Stromal Cells Limits Influenza A Virus-Induced Lung Injury in Mice

  2021cites this paper
• Effectiveness of neuraminidase inhibitors to prevent mortality in patients with laboratory-con fi rmed avian in fl uenza A H7N9 International Journal of Infectious Diseases

  2021cites this paper
• Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia

  2021cites this paper
• Characteristics of viral pneumonia in the COVID-19 era: an update

  2021cites this paper
• Long Term Respiratory Follow-Up for COVID-19 Patients a Multicenter Study

  2021cites this paper
• A NARRATIVE REVIEW OF INFLUENZA: A SEASONAL AND PANDEMIC DISEASE

  2021cites this paper
• Clinical impact of nosocomial infection with pandemic influenza A (H1N1) 2009 in a respiratory ward in Guangzhou

  2021cites this paper
• The Chronic Kidney Disease in Africa (CKD-Africa) collaboration: lessons from a new pan-African network

  2021cites this paper
• Point-of-Care Influenza Testing Impacts Clinical Decision, Patient Flow, and Length of Stay in Hospitalized Adults

  2020cites this paper
• Impact of early neuraminidase inhibitor treatment on clinical outcomes in patients with influenza B-related pneumonia: a multicenter cohort study

  2020cites this paper
• Antiviral Pneumonia to Treat Influenza Virus

  2020cites this paper
• FluA-p score: a novel prediction rule for mortality in influenza A-related pneumonia patients

  2020cites this paper
• Influenza-induced thrombocytopenia is dependent on the subtype and sialoglycan receptor and increases with virus pathogenicity.

  2020cites this paper
• The impact of early neuraminidase inhibitor therapy on clinical outcomes in patients hospitalised with influenza A-related pneumonia: a multicenter, retrospective study

  2020cites this paper
• Invasive pulmonary aspergillosis in immunocompetent patients hospitalised with influenza A-related pneumonia: a multicenter retrospective study

  2020cites this paper
• Derivation and validation of a prediction rule for mortality of patients with respiratory virus-related pneumonia (RV-p score)

  2020cites this paper
• Clinical characteristics and outcomes in adult patients hospitalized with influenza, respiratory syncytial virus and human metapneumovirus infections

  2020cites this paper
• Response to Doshi et al.

  2020cites this paper
• Clinical characteristics and outcomes of adult patients hospitalized with in uenza, respiratory syncytial virus and human metapneumovirus infections: a prospective, cohort study

  2020cites this paper
• Effectiveness of Neuraminidase Inhibitors to Prevent Mortality in Laboratory-Confirmed Avian Influenza A H7N9 Patients.

  2020cites this paper
• [Oseltamivir for the treatment of influenza in children and adolescents].

  2019cites this paper
• Oseltamivir for the treatment of influenza in children and adolescents

  2019cites this paper
• Influenza Infections and Emergent Viral Infections in Intensive Care Unit

  2019influential citation
• Effectiveness of the Neuraminidase Inhibitors: The Supporting Evidence Increases.

  2019cites this paper
• Emerging antibiotics for community-acquired pneumonia

  2019cites this paper
• Viral Pneumonia Requiring Differentiation from Acute and Progressive Diffuse Interstitial Lung Diseases

  2019cites this paper
• Challenges in Severe Influenza Pneumonia

  2019cites this paper
• EMAPII Monoclonal Antibody Ameliorates Influenza A Virus-Induced Lung Injury

  2018cites this paper
• Mortality and severity related factors during the admission: H1N1 pneumonia

  2018cites this paper
• Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study

  2018cites this paper
• Antiviral treatment for outpatient use during an influenza pandemic: a decision tree model of outcomes averted and cost-effectiveness

  2018cites this paper
• Systematic review of respiratory viral pathogens identified in adults with community-acquired pneumonia in Europe

  2017cites this paper
• Modelling of Pandemic Influenza in Canada: Predicted Burden and Hospital-Resource Adequacy

  2017cites this paper
• South African guideline for the management of community-acquired pneumonia in adults.

  2017cites this paper
• The pharmacological management of severe influenza infection – ‘existing and emerging therapies’

  2017cites this paper
• Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses

  2017cites this paper
• ICU-treated influenza A(H1N1) pdm09 infections more severe post pandemic than during 2009 pandemic: a retrospective analysis

  2017cites this paper
• ИНГИБИТОРЫ НЕЙРАМИНИДАЗЫ — ЗОЛОТОЙ СТАНДАРТ ПРОТИВОВИРУСНОЙ ТЕРАПИИ ГРИППА ТИПА А

  2017cites this paper
• Assessing the State of Knowledge Regarding the Effectiveness of Interventions to Contain Pandemic Influenza Transmission: A Systematic Review and Narrative Synthesis

  2016cites this paper
• A Narrative Review of Influenza: A Seasonal and Pandemic Disease

  2016cites this paper
• The neuraminidase inhibitors evidence of harms – in context

  2016cites this paper
• Antivirale Arzneimittel bei saisonaler und pandemischer Influenza

  2016cites this paper
• Antiviral Medications in Seasonal and Pandemic Influenza.

  2016cites this paper
• Interpandemic (seasonal) influenza

  2016cites this paper
• Reducing disease burden in an influenza pandemic by targeted delivery of neuraminidase inhibitors: mathematical models in the Australian context

  2016cites this paper
• Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09‐related pneumonia: an individual participant data meta‐analysis

  2015cites this paper